NESS ZIONA, Israel, October 6, 2015 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will participate in the Aegis Growth Conference, taking place at The Encore at Wynn Hotel in Las Vegas, NV from October 7-9, 2015.
BiondVax's CEO, Dr. Ron Babecoff, is scheduled to present on Thursday, October 8, 2015 at 2pm Pacific Time. The corporate presentation which Dr. Babecoff will present at the conference is available for download from the investor relations section of BiondVax's website.
At the conference there will be an opportunity for investors to meet one-on-one with Dr. Ron Babecoff. Investors interested in meeting with management should contact the Investor Relations team at BiondVax at firstname.lastname@example.org.
About BiondVax Pharmaceuticals Ltd
BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
For further information, please contact:
Limor Chen, Director of BD
Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
SOURCE BiondVax Pharmaceuticals Ltd.